Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.59 |
| ▸ | CTSD | P07339 | 7/20 | 0.59 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741988 | 1.00 | BACE1 (0.59) | BACE1CTSDBACE2KDM4E | |
| SCHEMBL5930076 | 0.99 | BACE1 (0.57) | BACE1CTSDBACE2KDM4E | |
| SCHEMBL5930079 | 0.99 | BACE1 (0.57) | BACE1CTSDBACE2KDM4E | |
| SCHEMBL5930243 | 0.96 | BACE1 (0.55) | BACE1CTSDBACE2 | |
| SCHEMBL5930246 | 0.96 | BACE1 (0.55) | BACE1CTSDBACE2 | |
| SCHEMBL5222893 | 0.84 | KLK5 (0.59) | BACE1CTSDBACE2 | |
| SCHEMBL5222884 | 0.84 | KLK5 (0.59) | BACE1CTSDBACE2 | |
| SCHEMBL6205577 | 0.84 | KLK5 (0.59) | BACE1CTSDBACE2 | |
| SCHEMBL4875199 | 0.84 | BACE1 (0.45) | BACE1CTSDBACE2KDM4E | |
| SCHEMBL5223745 | 0.84 | BACE1 (0.49) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1620438-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094430-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 264/4885BACE2 1/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | BACE1 4/4885CTSD 2080/4885BACE2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.